Founded as EnVision in 1998, VisionSense is now at the market penetration stage for its product, Visionsense Stereoscopic Vision System endoscope, which provides a 3D image for diagnosis or navigation for minimally invasive surgical procedures.
VisionSense already has sales in the US and Europe, and is planning an organized penetration of the market, either via its own marketing staff, or through distributors. The proceeds from the round are slated for this purpose, as well as for the development of new products.
Lewis Pell invested in VisionSense in 2004. Pell and Prof. Shlomo Ben-Haim have invested in dozens of start-ups and made more than $500 million in exits, including in Biosense, Instent, Disc-o-Tech Ltd., and X-Technologies.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments